NCT00603447 · REGISTRY CONDITION SEARCH

Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE1
Status at capture: COMPLETED
Registry last update: 2017-05-30

To evaluate the safety and maximum tolerated dose (MTD) of carfilzomib in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Participants With Adverse Events (AEs)

→

outcome · POSTED

Number of Participants With Dose-limiting Toxicities

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: Disease related: 1. Symptomatic multiple myeloma 2. Relapsed or progressive disease after at least one but no more than three prior therapeutic treatments or regimens for multiple myeloma 3. Prior therapeutic treatment regimens may have included bortezomib, lenalidomide, and/or thalidomide, among other agents. 4. If previously treated with lenalidomide or bortezomib, the subject must not have progressed during the first 3 months of treatment with the drug and must not have discontinued treatment due to lenalidomide intolerance (bortezomib intolerant subjects may enroll). 5. Measurable disease, as indicated by one or more of the following: * Serum M-protein ≥ 0.5 g/dL * Urine Bence-Jones protein ≥ 200 mg/24 h * If Serum Protein Electrophoresis is felt to be unreliable for routine M-protein measurement (particularly for patients with Immunoglobulin (Ig)A multiple myeloma), then quantitative immunoglobulin levels can be accepted. 6. Prior to enrollment, sites must provide evidence of myeloma progression/relapse, with start and stop dates of the most recent treatment regimen, as well as best tumor response to all prior treatment regimens. Demographic 7. Males and females ≥ 18 years of age 8. Life expectancy of more than three months 9. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2 Laboratory 10. Adequate hepatic function, with bilirubin \< 2 times the upper limit of normal (ULN) and alanine aminotransferase (ALT) \< 3 times ULN 11. Absolute neutrophil count (ANC) ≥ 1,000/mm³, hemoglobin ≥ 8 gm/dL, platelet count ≥ 50,000/ mm³ (≥ 30 × 10\^9/L if myeloma involvement in the bone marrow is \> 50%) * Screening ANC should be independent of granulocyte- and granulocyte/macrophage colony stimulating factor (G-CSF and GM-CSF) support for at least 1 week and of pegylated G-CSF for at least 2 weeks. * Subjects may receive red blood cell (RBC) or platelet transfusions, if clinically indicated, in accordance with institutional guidelines * Screening platelet count should be independent of platelet transfusions for at least 2 weeks 12. Calculated or measured creatinine clearance of ≥ 50 mL/minute, calculated using the formula of Cockcroft and Gault \[(140 - Age) x Mass (kg) / (72 x creatinine mg/dL)\]; multiply result by 0.85 (if female). Other generally accepted calculation methods can be substituted. Ethical/Other 13. Written informed consent in accordance with federal, local, and institutional guidelines 14. Females of childbearing potential (FCBP) must agree to ongoing pregnancy testing 15. FCBP\* must have a negative serum or urine pregnancy test, with a sensitivity of at least 50 mIU/mL within 10-14 days (US/RevAssist®) or 25 mIU/mL within 7-14 days (Canada/RevAidSM), prior to and again within 24 hours of starting lenalidomide and must either commit to continued abstinence from heterosexual intercourse or to use two methods of reliable birth control, including at least one highly effective method AND one additional effective method of birth control (contraception) AT THE SAME TIME, beginning 4 weeks prior to initiating treatment with lenalidomide, during therapy, during therapy delay, and continuing for 4 weeks following discontinuation of lenalidomide therapy. If a hormonal method (birth control pills, injections, patch or implants) or intrauterine device (IUD) is not medically possible for the subject, the subject may use another highly effective method or two barrier methods AT THE SAME TIME. 16. Male subjects must agree to NEVER have unprotected sexual contact with a female who can become pregnant and must agree to either completely abstain from sexual contact with females who are pregnant or are able to become pregnant, or he must use a latex condom EVERY TIME he engages in any sexual contact with females who are pregnant or may become pregnant while he is taking lenalidomide and for 4 weeks after he stops taking the drug, even if he has had a successful vasectomy. The subject must agree to inform his physician if he has had unprotected sexual contact with a female who can become pregnant or if he thinks FOR ANY REASON, that his sexual partner may be pregnant. 17. Male subjects cannot donate semen or sperm while taking lenalidomide. 18. All study participants must be registered into the mandatory RevAssist (US) or RevAid (Canada) programs and be willing and able to comply with the requirements of Rev Assist/RevAid 19. Subjects must adhere to the study visit schedule and other protocol requirements and receive outpatient treatment and laboratory monitoring at the institute that administers the drug 20. Subjects must agree to take enteric-coated aspirin 81-325 mg orally daily, or if history of prior thrombotic disease or allergy to aspirin, must be fully anticoagulated with warfarin (INR 2-3) or be treated with full-dose, low molecular weight heparin, as if to treat deep venous thrombosis (DVT)/pulmonary embolism. Exclusion Criteria: Disease related 1. Subjects with non-secretory or hyposecretory multiple myeloma, defined as \< 0.5 g/dL M-protein in serum, \< 200 mg/24 hr Bence Jones protein in urine, or disease only measured by serum free light chain (FLC) 2. Subjects who never achieved at least a durable minimal response (MR, ≥ 25% reduction in M-protein for at least 6 weeks) on any prior therapy 3. Corticosteroid therapy in a dose equivalent to dexamethasone ≥ 4 mg/day or prednisone ≥ 20 mg/day within 3 weeks prior to first dose 4. Use of any other experimental drug or therapy within 28 days of baseline 5. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) 6. Plasma cell leukemia 7. Waldenström's macroglobulinemia 8. Chemotherapy with approved or investigative anticancer therapeutics, including steroid therapy dose as defined above, within 3 weeks prior to first dose 9. Radiation therapy or immunotherapy within 4 weeks prior to first dose; localized radiation therapy within 1 week prior to first dose 10. Planned radiation therapy that occurs after the start of treatment 11. Participation in an investigational therapeutic study within 3 weeks or within 5 drug half-lives (t1/2) prior to first dose, whichever time is greater. Concurrent conditions 12. Pregnant or lactating females 13. History of allergy to boron or mannitol 14. Major surgery within 3 weeks prior to first dose 15. Congestive heart failure (New York Heart Association class III to IV), symptomatic ischemia, conduction abnormalities uncontrolled by conventional intervention or myocardial infarction in the previous six months 16. Uncontrolled hypertension 17. Acute active infection requiring systemic antibiotics, antivirals, or antifungals within two weeks prior to first dose 18. Known or suspected human immunodeficiency virus (HIV) infection, known HIV seropositivity, or active hepatitis A, B, or C infection 19. Non-hematologic malignancy within the past three years except 1. adequately treated basal cell or squamous cell skin cancer, 2. carcinoma in situ of the cervix, or 3. prostate cancer \< Gleason Grade 6 with stable prostate specific antigen (PSA) levels 20. Serious psychiatric or medical conditions that could interfere with treatment 21. Significant neuropathy (Grade 3, Grade 4, or Grade 2 with pain) at the time of the first dose and/or within 14 days before enrollment 22. Contraindication to any of the required concomitant drugs, including proton-pump inhibitor (e.g., lansoprazole), enteric-coated aspirin or other anticoagulant, or if a history of prior thrombotic disease, warfarin or low molecular weight heparin 23. Subjects in whom the required program of oral and intravenous fluid hydration is contraindicated, e.g., due to pre-existing pulmonary, cardiac, or renal impairment 24. Subjects with known or suspected amyloidosis 25. Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis 26. Prior carfilzomib treatment
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Treatment during Cycles 1 through 12 consisted of carfilzomib (15, 20, or 20/27 mg/m²) on Days 1, 2, 8, 9, 15, and 16; lenalidomide (10, 15, 20, or 25 mg) on Days 1 to 21; and low-dose dexamethasone (40 mg) given 30 minutes to 4 hours before the carfilzomib dose on Days 1, 8, and 15, as well as on Day 22. For Cycles 13 and higher, carfilzomib could be omitted on Days 8 and 9 at the investigator's discretion.
intervention Names
Drug: Carfilzomib
Drug: Lenalidomide
Drug: Dexamethasone
label
Carfilzomib + Lenalidomide + Dexamethasone
type
EXPERIMENTAL

interventions

arm Group Labels
Carfilzomib + Lenalidomide + Dexamethasone
description
Carfilzomib for Injection was administered intravenously over 10 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for the first 12 cycles. Each dose of Carfilzomib for Injection was normalized to body surface area.
name
Carfilzomib
other Names
Kyprolis®
type
DRUG
arm Group Labels
Carfilzomib + Lenalidomide + Dexamethasone
description
Lenalidomide was administered orally on Days 1 to 21 of each 28-day cycle.
name
Lenalidomide
other Names
REVLIMID®
type
DRUG
arm Group Labels
Carfilzomib + Lenalidomide + Dexamethasone
description
Dexamethasone 40 mg orally or intravenous equivalent was administered 30 minutes to 4 hours before carfilzomib on Days 1, 8, and 15, as well as on Day 22 of each 28-day cycle.
name
Dexamethasone
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 84
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Treatment-related are those AEs with possible or probable relationship to carfilzomib, lenalidomide or dexamethasone as assessed by the Investigator. The severity of each adverse event was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0, per the following: Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death. Serious adverse events were defined as AEs meeting one of the following: death, life-threatening, required or prolonged in-patient hospitalization, resulted in persistent or significant disability/incapacity, a congenital anomaly/birth defect in the offspring of an exposed participant, important medical events that may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed above, or pregnancy or suspected pregnancy.
measure
Number of Participants With Adverse Events (AEs)
time Frame
From the first dose of study drug until 30 days after the last dose; 1 to 52 months, with an average of 12 months.
description
Dose-limiting toxicity was defined as any of the following events assessed as related to carfilzomib, lenalidomide, or dexamethasone: Nonhematologic * ≥ Grade 2 neuropathy with pain * ≥ Grade 3 nonhematologic toxicity (excluding nausea, vomiting, diarrhea, hyperglycemia due to dexamethasone, and rash due to lenalidomide) * ≥ Grade 3 nausea, vomiting, or diarrhea uncontrolled by maximal supportive therapy * ≥ Grade 4 fatigue persisting \> 7 days * Treatment delay for toxicity \> 21 days Hematologic * Grade 4 neutropenia (absolute neutrophil count \[ANC\] \< 500/mm³) \> 7 days * Febrile neutropenia (ANC \< 1,000/mm³ with fever ≥ 38.3ºC) * Grade 4 thrombocytopenia (platelets \< 25,000/mm³) for \> 7 days despite holding treatment, or Grade 3 or 4 thrombocytopenia associated with bleeding * Treatment delay for toxicity \> 21 days. The maximum-tolerated dose was defined as the dose level below which a drug-related DLT was observed in ≥ 33% of participants in a cohort.
measure
Number of Participants With Dose-limiting Toxicities
time Frame
Cycle 1, 28 days

Full study description

brief Summary: To evaluate the safety and maximum tolerated dose (MTD) of carfilzomib in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma

Source references

references

citation
Wang M, Martin T, Bensinger W, Alsina M, Siegel DS, Kavalerchik E, Huang M, Orlowski RZ, Niesvizky R. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood. 2013 Oct 31;122(18):3122-8. doi: 10.1182/blood-2013-07-511170. Epub 2013 Sep 6.
pmid
24014245
type
DERIVED
citation
Niesvizky R, Martin TG 3rd, Bensinger WI, Alsina M, Siegel DS, Kunkel LA, Wong AF, Lee S, Orlowski RZ, Wang M. Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Clin Cancer Res. 2013 Apr 15;19(8):2248-56. doi: 10.1158/1078-0432.CCR-12-3352. Epub 2013 Feb 27.
pmid
23447001
type
DERIVED

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-31801bb58ed998f268b9
requested nct id
NCT00603447
primary nct id
NCT00603447
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
fb0139b85de125cf152997dfdbd20626908edf5fc45aca4db4143d5168defd04
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-31801bb58ed998f268b9
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00603447
occurrences
context exact
NCT00603447
end
11
exact text
NCT00603447
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/299/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
3b1efe8e899cbedb66626e8e709ef0e50047db663c879ebff886a49d691cf07d
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice